Journal of Medicinal Chemistry · 1999 · 85 citations · 17 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyStructure-activity RelationshipsAdhesion MoleculesDrug-receptor InteractionsIntegrin SignalingLigand BindingPlatelet AggregationPotency OptimizationAmination ReactionsChemical Synthesis Of AnaloguesIntegrin Alpha Iib Beta 3 SignalingIntegrin AntagonistsIntegrin-binding LigandsPlatelet Aggregation InhibitionPlatelet IntegrinsProtein Structural Changes
Starting with lead compound 2, we sought to increase the selectivity for alpha(v)beta(3)-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent alpha to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of alpha(v)beta(3). In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for alpha(v)beta(3)-mediated adhesion versus alpha(IIb)beta(3)-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the alpha-substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective alpha(v)beta(3) antagonist 3h was found to be a potent inhibitor of alpha(v)beta(3)-mediated cell migration.
17
V. Wayne Engleman, G. Allen Nickols, F. Patrick Ross et al. · Journal of Clinical Investigation · 1997 · 287 citations · Full text